Evaluation of the sirna pf-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (monet study) Ophthalmology, 06/12/2012

Nguyen QD et al. – In this, early, underpowered study evaluating treatments for neovascular age–related macular degeneration (AMD), the combination of PF with ranibizumab led to an average gain in best–corrected visual acuity (BCVA) that was more than with ranibizumab monotherapy. No safety concerns were identified.

Read this article on Ophthalmology

Print Article | Back to Articles

Stay current on the latest literature, research and clinical news
Get special communications and offers from MDLinx and our sponsors
Receive invitations to paid market research

View Samples and Register

Stay current - Media Tool

Newsletter

RSS

Facebook

Receive free subspecialty
"5-minute updates" via email

Send the E-mail Newsletter to a Colleague

♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦

♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦

♦ Follow Us on Facebook

Search the latest
Physician Assistant Jobs
@MDLinx Career Center
View the full listing of physician jobs

Enter your email address and your password will be sent to you.
Email:

E-mail:
Password:
	Remember me Forgot your password?